secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-031719
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine Q1 net loss $49.1M; progress on Wilson, AATD programs
--------------------------------------------------------------------

- Net loss of $49.1M in Q1 2026 vs $51.9M in Q1 2025; R&D down to $34.1M.
- Cash position $149.2M as of March 31, 2026, providing runway into 2027.
- On track to file IND/CTA for PM577 (Wilson Disease) in H1 2026 and PM647 (AATD) mid-2026.
- Appointed Svetlana Makhni as CFO in April 2026; regulatory dialogue ongoing for PM359 BLA.
- Initial clinical data from PM577 and PM647 expected in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828026031719/0001628280-26-031719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828026031719/prme-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-031719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer